ST Pharm Co.,Ltd. (KOSDAQ:237690)

Market Cap	3.16T +95.5%
Revenue (ttm)	318.32B +14.2%
Net Income	36.89B +13.9%
EPS	1,795.21 +6.2%
Shares Out	20.78M
PE Ratio	84.84
Forward PE	49.69
Dividend	500.00 (0.33%)
Ex-Dividend Date	Mar 30, 2026

Volume	241,478
Average Volume	221,212
Open	144,500
Previous Close	147,100
Day's Range	144,300 - 157,500
52-Week Range	66,600 - 166,300
Beta	0.34
RSI	57.16
Earnings Date	Feb 5, 2026

About ST Pharm

ST Pharm Co.,Ltd., provides manufacturing services for active pharmaceutical ingredient and intermediate. The company offers small molecule and generics, an ingredient for treating viral infections; oligonucleotide based products, such as siRNA/microRNA, antisense, aptamer, decoys, and other novel oligos; monomer; and mRNA for vaccines and therapeutics. It also offers pre-clinical and bioanalytical research and development solutions. The company was formerly known as Samchully Pharmaceutical Company., Ltd. ST Pharm Co. Ltd. was founded in 1983 ...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1983
• Employees: 655
• Stock Exchange: KOSDAQ
• Ticker Symbol: 237690

Financial Performance

In 2024, ST Pharm's revenue was 273.75 billion, a decrease of -3.94% compared to the previous year's 284.99 billion. Earnings were 34.71 billion, an increase of 77.27%.